SELECT COUNTRY

VIEW ALL
AFRICA
AMERICAS
ASIA
EUROPE
OCEANIA

UNITED STATES: LATEST INTERVIEWS MORE INTERVIEWS

Katrin Rupalla
CEO, YMMUNOBIO
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200, we have obtained orphan drug status from FDA for the treatment of liver cancer."
United States
Pharma & Life Sciences
Stefan Randl & Paul Spencer
HEAD OF DRUG SUBSTANCE (SR), HEAD OF DRUG DELIVERY & PRODUCT...
"The US leads innovation, so if you are not heavily invested there in pharma, you are in trouble. Lots of our clients are shifting their production from Asia, so the US will remain critical to Evonik Health Care’s growth."
United States
Pharma & Life Sciences
Roger Erickson
CEO AND FOUNDER, INTERBIOME
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
United States
Pharma & Life Sciences
Jan Kengelbach
CEO, AENOVA GROUP
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."
United States
Pharma & Life Sciences

UNITED STATES: LATEST ARTICLES

Mining
United States

Mine Water Stewardship in Arizona

June 01, 2023
Arizona & Nevada Mining 2023
Expert Opinion Article by Terry Braun, President, North America, SRK Consulting
Mining
United States

Protecting Supply Chains and Prosperity: The Case for Reducing US Dependency on Foreign Critical Minerals

October 12, 2022
Expert Opinion Article by Eric Mears, Vice President, Haley & Aldrich
Mining
United States

Arizona Copper Production: Securing a Domestic Supply Chain

October 10, 2022
Arizona, leading the charge towards the green transition
MORE ARTICLES

UNITED STATES: RECENTLY RELEASED PUBLICATIONS

United States Life Sciences 2023

May 19, 2023

United States Life Sciences 2023 - Digital Interactive

April 24, 2023

Arizona & Nevada Mining 2023

February 02, 2023

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL